Tag: remicade biosimilar industry forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Remicade Biosimilar Market Expected To Expand Between 2025 And 2029?

Recent years have witnessed an exponential increase in the remicade biosimilar market size. This market is projected to expand from $3.95 billion in 2024 to $4.89 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 23.8%. Factors contributing to this historic growth include the introduction of remicade (infliximab), alongside biotechnology advancements, the expiry of biologics patents, the establishment of regulatory pathways, and pressures related to healthcare costs.

The remicade biosimilar market size is set for significant expansion in the coming years, with forecasts indicating a rise to $10.89 billion by 2029, driven by a compound annual growth rate (CAGR) of 22.2%. This projected growth throughout the forecast period is influenced by several factors, including patent expirations, an increasing need for cost-effective therapies, progress in biosimilar pipeline development, favorable reimbursement policies, and market consolidation. Noteworthy trends anticipated during this period involve changes in physician prescribing behavior, strategies for biosimilar lifecycle management, the adoption of specific biosimilar naming conventions, considerations of biosimilar interchangeability, and the accumulation of biosimilar real-world evidence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Remicade Biosimilar Industry?

The remicade biosimilar market is poised for growth, primarily driven by the rising incidence of autoimmune diseases. These are disorders where the immune system mistakenly attacks and damages the body’s own tissues and organs. Remicade biosimilars serve as an effective therapeutic option for treating such conditions, helping to manage symptoms and reduce associated inflammation. Supporting this trend, data from Public Health Scotland, a national organization based in Scotland, indicated in July 2023 that newly diagnosed multiple sclerosis (MS) patients in 2022 increased to 87.2%, up from 85.7% in 2020, with 491 new cases reported, leading to a total of 6,359 cases in 2022. This consistent increase in autoimmune disease cases is therefore a significant factor propelling the expansion of the remicade biosimilar market.

What Are The Major Segment Categories Driving The Remicade Biosimilar Market Growth?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Long-Term Trends Will Shape The Future Growth Of The Remicade Biosimilar Industry?

A significant and growing trend within the Remicade biosimilar market is product innovation. Leading firms active in this sector are engaged in creating novel products to maintain their competitive standing. An illustration of this is Amgen Inc., a US-based biotechnology company, introducing Amjevita, a biosimilar iteration of AbbVie’s Humira, in the US in January 2023, engineered to match the safety and efficacy of its reference product. As the initial biosimilar for Humira, Amjevita is projected to contend for market share against it. Humira, a biological medication prescribed for numerous autoimmune conditions like rheumatoid arthritis and Crohn’s disease, stands among the world’s priciest pharmaceuticals, bringing in billions of dollars in annual sales for AbbVie. Amjevita is anticipated to be considerably more affordable and, beyond cost savings, it can also present patients with a broader array of treatment alternatives.

Who Are The Core Companies Influencing The Remicade Biosimilar Market Landscape?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Remicade Biosimilar Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2025, By The Business Research Company

Biostimulants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biostimulants-global-market-report

Agroscience Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agroscience-global-market-report

Agricultural Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Remicade Biosimilar Sector?

Recent years have seen tremendous growth in the remicade biosimilar market size. It is projected to escalate from $3.95 billion in 2024 to $4.89 billion in 2025, flourishing at a compound annual growth rate (CAGR) of 23.8%. The phenomenal expansion during the historic period is primarily attributed to factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, establishment of regulatory pathways, and the pressure of healthcare costs.

The market size for the remicade biosimilar is predicted to experience a significant escalation in the coming years. It is projected to reach “$10.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 22.2%. The anticipated expansion during the forecast period is attributed to various factors such as patent expiry, increased need for affordable treatments, the development of biosimilar pipelines, reimbursement policies, and market consolidation. Key trends during this period are expected to be physician prescription habits, management of the biosimilar lifecycle, naming protocols for biosimilars, interchangeability of biosimilars, and real-world evidence of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Forces Are Driving The Growth Of The Remicade Biosimilar Market?

The remicade biosimilar market is anticipated to expand due to an increase in the prevalence of autoimmune diseases. These conditions involve the immune system erroneously damaging the body’s tissues and organs. As an effective treatment option, remicade biosimilars are used to manage the symptoms and lower the inflammation that comes with these diseases. For example, according to Public Health Scotland’s data in July 2023, in 2022, the number of newly diagnosed multiple sclerosis (MS) patients rose to 87.2%, an increase from 85.7% in 2020, with 491 new cases documented, adding up to a total of 6,359. Therefore, the escalating prevalence of autoimmune diseases is proving to be a significant growth driver for the remicade biosimilar market.

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Long-Term Trends Are Likely To Affect The Remicade Biosimilar Market?

A prominent trend in the Remicade biosimilar market is product innovation, with leading companies endeavouring to create novel products to maintain their market standing. For example, in January 2023, Amgen Inc., a biotech firm based in the US, released Amjevita, a biosimilar of AbbVie’s Humira that matches the original drug’s safety and effectiveness. This version is the inaugural biosimilar of Humira and aims to vie with Humira for market visibility. A biologic medication, it is utilised in treating a variety of autoimmune disorders, including rheumatoid arthritis and Crohn’s disease. Among the world’s priciest medications, it brings in billions of dollars annually for AbbVie. Amjevita’s price is expected to be considerably less, potentially facilitating cost savings and augmenting treatment possibilities for patients.

Which Companies Currently Dominate The Competitive Landscape In The Remicade Biosimilar Industry?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Geographic Regions Are Driving Demand In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Remicade Biosimilar Sector?

Recent years have seen tremendous growth in the remicade biosimilar market size. It is projected to escalate from $3.95 billion in 2024 to $4.89 billion in 2025, flourishing at a compound annual growth rate (CAGR) of 23.8%. The phenomenal expansion during the historic period is primarily attributed to factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, establishment of regulatory pathways, and the pressure of healthcare costs.

The market size for the remicade biosimilar is predicted to experience a significant escalation in the coming years. It is projected to reach “$10.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 22.2%. The anticipated expansion during the forecast period is attributed to various factors such as patent expiry, increased need for affordable treatments, the development of biosimilar pipelines, reimbursement policies, and market consolidation. Key trends during this period are expected to be physician prescription habits, management of the biosimilar lifecycle, naming protocols for biosimilars, interchangeability of biosimilars, and real-world evidence of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Forces Are Driving The Growth Of The Remicade Biosimilar Market?

The remicade biosimilar market is anticipated to expand due to an increase in the prevalence of autoimmune diseases. These conditions involve the immune system erroneously damaging the body’s tissues and organs. As an effective treatment option, remicade biosimilars are used to manage the symptoms and lower the inflammation that comes with these diseases. For example, according to Public Health Scotland’s data in July 2023, in 2022, the number of newly diagnosed multiple sclerosis (MS) patients rose to 87.2%, an increase from 85.7% in 2020, with 491 new cases documented, adding up to a total of 6,359. Therefore, the escalating prevalence of autoimmune diseases is proving to be a significant growth driver for the remicade biosimilar market.

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Long-Term Trends Are Likely To Affect The Remicade Biosimilar Market?

A prominent trend in the Remicade biosimilar market is product innovation, with leading companies endeavouring to create novel products to maintain their market standing. For example, in January 2023, Amgen Inc., a biotech firm based in the US, released Amjevita, a biosimilar of AbbVie’s Humira that matches the original drug’s safety and effectiveness. This version is the inaugural biosimilar of Humira and aims to vie with Humira for market visibility. A biologic medication, it is utilised in treating a variety of autoimmune disorders, including rheumatoid arthritis and Crohn’s disease. Among the world’s priciest medications, it brings in billions of dollars annually for AbbVie. Amjevita’s price is expected to be considerably less, potentially facilitating cost savings and augmenting treatment possibilities for patients.

Which Companies Currently Dominate The Competitive Landscape In The Remicade Biosimilar Industry?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Geographic Regions Are Driving Demand In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Remicade Biosimilar Sector?

Recent years have seen tremendous growth in the remicade biosimilar market size. It is projected to escalate from $3.95 billion in 2024 to $4.89 billion in 2025, flourishing at a compound annual growth rate (CAGR) of 23.8%. The phenomenal expansion during the historic period is primarily attributed to factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, establishment of regulatory pathways, and the pressure of healthcare costs.

The market size for the remicade biosimilar is predicted to experience a significant escalation in the coming years. It is projected to reach “$10.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 22.2%. The anticipated expansion during the forecast period is attributed to various factors such as patent expiry, increased need for affordable treatments, the development of biosimilar pipelines, reimbursement policies, and market consolidation. Key trends during this period are expected to be physician prescription habits, management of the biosimilar lifecycle, naming protocols for biosimilars, interchangeability of biosimilars, and real-world evidence of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Forces Are Driving The Growth Of The Remicade Biosimilar Market?

The remicade biosimilar market is anticipated to expand due to an increase in the prevalence of autoimmune diseases. These conditions involve the immune system erroneously damaging the body’s tissues and organs. As an effective treatment option, remicade biosimilars are used to manage the symptoms and lower the inflammation that comes with these diseases. For example, according to Public Health Scotland’s data in July 2023, in 2022, the number of newly diagnosed multiple sclerosis (MS) patients rose to 87.2%, an increase from 85.7% in 2020, with 491 new cases documented, adding up to a total of 6,359. Therefore, the escalating prevalence of autoimmune diseases is proving to be a significant growth driver for the remicade biosimilar market.

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Long-Term Trends Are Likely To Affect The Remicade Biosimilar Market?

A prominent trend in the Remicade biosimilar market is product innovation, with leading companies endeavouring to create novel products to maintain their market standing. For example, in January 2023, Amgen Inc., a biotech firm based in the US, released Amjevita, a biosimilar of AbbVie’s Humira that matches the original drug’s safety and effectiveness. This version is the inaugural biosimilar of Humira and aims to vie with Humira for market visibility. A biologic medication, it is utilised in treating a variety of autoimmune disorders, including rheumatoid arthritis and Crohn’s disease. Among the world’s priciest medications, it brings in billions of dollars annually for AbbVie. Amjevita’s price is expected to be considerably less, potentially facilitating cost savings and augmenting treatment possibilities for patients.

Which Companies Currently Dominate The Competitive Landscape In The Remicade Biosimilar Industry?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Geographic Regions Are Driving Demand In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Remicade Biosimilar Industry?

In recent times, the market size for remicade biosimilar has seen enormous growth. The market, which was valued at $3.95 billion in 2024, is anticipated to surge to $4.89 billion in 2025, yielding a compound annual growth rate (CAGR) of 23.8%. This robust growth in the historical period is a result of factors such as the introduction of remicade (infliximab), advancement in biotechnology, expiration of biologics patent, establishment of regulatory pathways, and the pressure of healthcare costs.

In the coming years, the Remicade biosimilar market is predicted to experience an explosive surge in its size. It is forecasted to escalate to $10.89 billion by 2029, with a compound annual growth rate (CAGR) of 22.2%. Factors like patent expirations, an increase in demand for affordable treatment options, development of the biosimilar pipeline, reimbursement policies and market consolidation can be credited for the projected growth during this period. Other significant trends for this forecast period include the prescribing habits of physicians, management of biosimilar life cycles, naming strategies for biosimilars, their interchangeability, and real-world evidence of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Forces Are Driving The Growth Of The Remicade Biosimilar Industry?

The surge in the occurrence of autoimmune diseases is anticipated to fuel the expansion of the remicade biosimilar market. These types of diseases are when the body’s immune system inaccurately damages its own tissues and organs. Remicade biosimilars provide an effective therapeutic treatment to alleviate the symptoms and inflammation related to these conditions. For instance, in July 2023, based on data from Public Health Scotland, a national Scotland-based organization, the number of newly diagnosed patients with multiple sclerosis (MS) in 2022 rose to 87.2%, up from 85.7% in 2020, resulting in 491 new cases and culminating in a total of 6,359 cases in 2022. As a result, the surge in autoimmune diseases is contributing to the expansion of the remicade biosimilar market.

What Is The Overview Of Market Segmentation In The Remicade Biosimilar Industry?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Future Market Trends Are Projected For The Remicade Biosimilar Industry?

The rising trend of increased investments is becoming increasingly significant in the proteasome inhibitors market. Numerous large-scale companies operating within this sector are investing significantly in the development and commercialization of proteasome inhibitors. These inhibitors are essential for advancing research and introducing new treatments in the market. In a recent example, in September 2022, QLi5 Therapeutics GmbH, a Germany-based company that develops new-class proteasome inhibitors, secured an investment of $10.96 million (EUR 10 million). This investment was received from investors such as SV Investment and KHAN Technology Transfer Fund I, both Germany-based venture capital firms, in addition to Atinum Investment Co., Ltd. and Daol Investment & Securities Co., Ltd., both venture capitalist firms based in South Korea. The primary objective of these investments is to develop innovative proteasome inhibitors to treat cancer and inflammatory and autoimmune diseases. This funding will help QLi5 to further advance its unique pipeline of proteasome inhibitors to the commencement of clinical trials for various indications.

Who Are The Primary Players Operating Across The Global Remicade Biosimilar Market?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Offers The Most Growth Potential For The Remicade Biosimilar Market Through 2029?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Remicade Biosimilar Market Grown from 2024 to 2025?

The market size for remicade biosimilar has seen exponential expansion in the past few years. The forecast suggests that it will rise from a value of $3.95 billion in 2024 to $4.93 billion in 2025, marking a compound annual growth rate (CAGR) of 24.9%. Factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, the establishment of regulatory pathways, and the pressure to decrease healthcare costs contributed to the historical growth of the market.

What Growth Rate Is Anticipated for the Remicade Biosimilar Market in the Coming Years?

In the forthcoming years, there’s a predicted surge in the remicade biosimilar market, which is set to expand to $11.07 billion by 2029 with a compound annual growth rate (CAGR) of 22.4%. This growth during the prediction period can be tied to factors such as patent expiry, increased call for affordable treatment, the advancement of biosimilars pipeline, strategies around reimbursement, and market amalgamation. Key trends likely to be seen in the estimated period include changes in physician prescribing habits, stewardship of biosimilar lifecycle, conventions in naming biosimilars, interchangeability of biosimilars, and the practical application of biosimilar evidence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

Who Are the Leading Companies in the Remicade Biosimilar Market?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

What Are the Key Drivers of the Remicade Biosimilar Market?

The escalation in autoimmune diseases occurrence is anticipated to fuel the expansion of the remicade biosimilar market in the future. Autoimmune diseases are conditions wherein the body’s immune system erroneously assaults and harms its tissues and organs. Remicade biosimilars are utilized to treat autoimmune diseases by offering an effective solution to handle symptoms and alleviate inflammation connected to them. For instance, Public Health Scotland, a Scotland-based national entity, noted that in July 2023, the percentage of newly diagnosed multiple sclerosis (MS) patients rose to 87.2% in 2022, an increase from 85.7% in 2020, with 491 new diagnoses reported, bringing the total to 6,359 in 2022. Consequently, the escalating number of autoimmune diseases is contributing to the growing remicade biosimilar market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

What Are the Key Market Segments in the Remicade Biosimilar Industry?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Are the Latest Trends in the Remicade Biosimilar Market?

In the Remicade biosimilar market, a primary trending strategy is product innovation. Major participants in this market like Amgen Inc., a biotech firm based in the U.S, are inventing creative solutions to maintain their market stand. For example, in January 2023, Amgen introduced Amjevita, a biosimilar of AbbVie’s Humira, into the U.S. market. This alternative to Humira has been created with an aim to be just as safe and effective as the original. The launch of Amjevita, the first biosimilar to Humira, poses significant competition for market portion. The pharmaceutical is a biological drug used in the treatment of several autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. Despite being among the priciest drugs globally, it alone brings in billions of annual sales for AbbVie. However, Amjevita is projected to be substantially cheaper, providing not just cost savings but also expanding treatment options for patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

What Are the Key Regional Markets in the Remicade Biosimilar Industry?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952

This Report Delivers Insight On:

1. How big is the remicade biosimilar market, and how is it changing globally?

2. Who are the major companies in the remicade biosimilar market, and how are they performing?

3. What are the key opportunities and risks in the remicade biosimilar market right now?

4. Which products or customer segments are growing the most in the remicade biosimilar market?

5. What factors are helping or slowing down the growth of the remicade biosimilar market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the remicade biosimilar industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Remicade Biosimilar Market Size from 2025 to 2034?

The market size for remicade biosimilar has seen exponential expansion in the past few years. The forecast suggests that it will rise from a value of $3.95 billion in 2024 to $4.93 billion in 2025, marking a compound annual growth rate (CAGR) of 24.9%. Factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, the establishment of regulatory pathways, and the pressure to decrease healthcare costs contributed to the historical growth of the market.

In the forthcoming years, there’s a predicted surge in the remicade biosimilar market, which is set to expand to $11.07 billion by 2029 with a compound annual growth rate (CAGR) of 22.4%. This growth during the prediction period can be tied to factors such as patent expiry, increased call for affordable treatment, the advancement of biosimilars pipeline, strategies around reimbursement, and market amalgamation. Key trends likely to be seen in the estimated period include changes in physician prescribing habits, stewardship of biosimilar lifecycle, conventions in naming biosimilars, interchangeability of biosimilars, and the practical application of biosimilar evidence.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Are the Core Market Drivers Propelling Growth in the Remicade Biosimilar Industry?

The escalation in autoimmune diseases occurrence is anticipated to fuel the expansion of the remicade biosimilar market in the future. Autoimmune diseases are conditions wherein the body’s immune system erroneously assaults and harms its tissues and organs. Remicade biosimilars are utilized to treat autoimmune diseases by offering an effective solution to handle symptoms and alleviate inflammation connected to them. For instance, Public Health Scotland, a Scotland-based national entity, noted that in July 2023, the percentage of newly diagnosed multiple sclerosis (MS) patients rose to 87.2% in 2022, an increase from 85.7% in 2020, with 491 new diagnoses reported, bringing the total to 6,359 in 2022. Consequently, the escalating number of autoimmune diseases is contributing to the growing remicade biosimilar market.

How Is the Remicade Biosimilar Market Segmented?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Which Regions Are Driving the Next Phase of the Remicade Biosimilar Market Growth?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Remicade Biosimilar Industry?

In the Remicade biosimilar market, a primary trending strategy is product innovation. Major participants in this market like Amgen Inc., a biotech firm based in the U.S, are inventing creative solutions to maintain their market stand. For example, in January 2023, Amgen introduced Amjevita, a biosimilar of AbbVie’s Humira, into the U.S. market. This alternative to Humira has been created with an aim to be just as safe and effective as the original. The launch of Amjevita, the first biosimilar to Humira, poses significant competition for market portion. The pharmaceutical is a biological drug used in the treatment of several autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. Despite being among the priciest drugs globally, it alone brings in billions of annual sales for AbbVie. However, Amjevita is projected to be substantially cheaper, providing not just cost savings but also expanding treatment options for patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

How Is the Remicade Biosimilar Market Defined and What Are Its Core Parameters?

Remicade biosimilar refers to a biological drug like Remicade used to treat certain autoimmune diseases in adults and children. It treats autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theRemicade Biosimilar Market?

A surge in autoimmune diseases, conditions where the body’s immune system unknowingly harms its own organs and tissues, are predicted to enhance the progression of the remicade biosimilar market. Remicade biosimilars offer a potent treatment option to manage symptoms and alleviate inflammation associated with these diseases. For example, as per the Public Health Scotland’s data, an organization based in Scotland, there was an increase in newly diagnosed multiple sclerosis (MS) patients to 87.2% in 2022, a rise from 85.7% in 2020. This resulted in an uptick of 491 fresh cases, taking the total tally to 6,359 in 2022. Hence, the mounting incidence of autoimmune diseases is fueling the remicade biosimilar market’s expansion.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

#What is the Projected CAGR for the Remicade Biosimilar Market Size from 2025 to 2034?

The market size for remicade biosimilar has experienced significant expansion in the past few years. It is projected to surge from $3.95 billion in 2024 to $4.93 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 24.9%. Key factors contributing to this historical growth include the debut of remicade (infliximab), advancements in biotechnology, the expiry of biologics patents, the establishment of regulatory pathways, and pressures on healthcare costs.

Anticipated to experience substantial growth in the forthcoming years, the remicade biosimilar market is set to expand to $11.07 billion in 2029, with a compound annual growth rate (CAGR) of 22.4%. The factors contributing to the potential growth during the predicted period include patent terminations, an increase in the need for cost-efficient treatments, development of biosimilar pipelines, reimbursement strategies, and market amalgamation. The main trends to watch during the prognosticated period will be the prescribing habits of physicians, management of the biosimilar lifecycle, naming standards for biosimilars, the interchangeability of biosimilars, and real-world evidence related to biosimilars.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952

What Key Market Trends and Innovations Are Shaping the Future of theRemicade Biosimilar Industry?

The Remicade biosimilar market is seeing a rise in product innovation, a trend coming to prominence as key players in the sector strive to hold their market position by offering novel solutions. For example, in January 2023, Amgen Inc., a biotechnology company based in the US, introduced a biosimilar version of AbbVie’s Humira called Amjevita. As the first of its kind, Amjevita is designed to be as effective and safe as its original counterpart and is expected to rival Humira in market share. Amjevita, a pharmacological product for treating several autoimmune conditions like rheumatoid arthritis and Crohn’s disease, is anticipated to be significantly more affordable than Humira, which is one of the most expensive drugs globally and generates billions in annual revenue for AbbVie. Besides the cost advantage, Amjevita could also expand the range of treatment options available to patients.

Which Companies Are Leading the Charge in Expanding theRemicade Biosimilar Market Growth?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

How is the Global Remicade Biosimilar Market Segemented?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Which Geographics are Influencing the Growth of the Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Remicade Biosimilar Maret 2025, By The Business Research Company:

Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery

https://www.thebusinessresearchcompany.com/report/biologics-market

Pharmaceutical API Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Agricultural Biologics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: